Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of oral BGJ398 in advanced FGFR-altered solid tumors
NL-OMON45230Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of infigratinib in Non-hematologic malignancy and transitional cell carcinoma (TCC) (4 arms), sponsored by Novartis. Primary endpoint: Dose-limiting toxicities. Started Dec 2009; status: active, not recruiting.
02
Drugs
infigratinib
03
Conditions
Non-hematologic malignancytransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON45230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45230.